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g.2012.0Abstract Exposure to the dengue virus (DENV) evokes a variety of genetically-controlled immuno-
logical responses. Genetic variants involved in viral entry, replication and innate immunity pathways
play an important role in the causal pathway of dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS). Here we have reviewed implications of some genetic polymorphisms of the pathways
related to DENV infection susceptibility, protection and severity. Large case-control studies exam-
ining a variety of single-nucleotide polymorphisms (SNPs) in a variety of genes have been performed
in DENV patients in some countries. SNP gene candidates that have shown associations with DENV
infection are mannose-binding lectin (MBL), interleukin (IL)-4, IL-6, IL-10, interleukin-1 receptor
antagonist (IL-1RA), toll-like receptor 4 (TLR4), cytotoxic T-lymphocyte antigen 4 (CTLA-4),
tumor necrosis factor (TNF)-a, transforming growth factor (TGF)-b1, Fcc receptor II (FccRII),
vitamin D receptor (VDR), interferon (IFN)-c, human platelet antigens (HPA), transporters associ-
ated with antigen processing (TAP), dendritic cell-speciﬁc ICAM3-grabbing non-integrin (DC-
SIGN) and Janus kinase 1 (JAK1), although some of these genes failed to show statistical signiﬁ-
cance. Brieﬂy, polymorphism in TNF-a, FccRII, CTLA-4, TGF-b1, HPA, DC-SIGN, TAP and
JAK1 genes has been associated with DHF/DSS development. Polymorphism in MBL2 gene was
shown to be associated with thrombocytopenia and increased risk of DHF development. Inpical and Infection Diseases
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ussalam, Banda Aceh 23111,
hoo.com (H. Harapan).
Shams University.
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8.003
2 H. Harapan et al.contrary, polymorphism in VDR gene shows moderate associations with resistance to the most
severe form of DHF. However, neutral associations have been reported for IL-4 promoters, IL-
1RA, IFN-c, IL-6, TLR4 and IL-10 gene polymorphism. In conclusion, there are strong evidences
from several epidemiological studies indicating host genetic factors as important components in
DENV infection susceptibility, protection and severity.
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of major international public health threat. DENV cause a
spectrum of disease in humans, ranging from dengue fever
(DF) to a severe, life-threatening syndrome called dengue hem-
orrhagic fever/dengue shock syndrome (DHF/DSS). It is esti-
mated that 50 million dengue infections occur annually
worldwide [1] and it has increased dramatically in recent years
[2]. Approximately 2.5 billion people live in dengue endemic
countries [1] and two ﬁfths of the world’s population are at risk
from DENV [3].
Clinical outcome following secondary DENV infection ap-
pears to be related to the extent to which viral spread is limited
by innate immunity, DENV-speciﬁc antibody and DENV spe-
ciﬁc T cells [4]. Perturbations in immune responses, augmented
virus uptake, and delayed virus clearance may result in in-
creased pathogenicity of dengue infections [5]. Vast majority
of DENV infections result in no symptoms or a mild febrile ill-
ness, less than 2% of individuals infected with DENV develop
DHF, strongly suggesting the important role of host genetic
factors [5]. Halstead et al. [6] found that although multiple
DENV serotypes circulate in West Africa, there have been
no reports of DHF. They also found an absence of DHF/
DSS in the Haitian population despite hyperendemic transmis-
sion of DENV serotypes. Furthermore, blacks were less likelyto be hospitalized during Cuban DENV epidemics [5].
Although pre-existing immunity may be a confounding factor,
these reports argue strongly that genetic predisposition is an
important factor as well.
Polymorphisms in cytokine regulatory gene regions have
been described, some of these polymorphisms seem to correlate
with its production, potentially conferring the ﬂexibility to im-
mune response. The presence of certain genotypes inﬂuences
the course of both viral and bacterial infections [7]. Variations
in immune response as a consequence of polymorphisms in
regulatory regions of cytokine genes and other genes may have
inﬂuence on the DENV infection susceptibility and outcome
[8]. In addition, genetic variants involved in viral entry and
replication may play an important role in the causal pathway
of DHF [9]. Here we have reviewed the implications of some
non-human leukocyte antigen (HLA) gene polymorphisms to
susceptibility, protection and severity of DENV infection
based on publication from some of the countries.
2. Discussion
2.1. Mannose-binding lectin (MBL)
A majority of studies examining complement-DENV interac-
tions have focused on the role of complement in the context of
DHF/DSS pathogenesis [10]. In a prospective study, nonstruc-
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Moreover, levels of NS1 and several complement proteins were
correlated with dengue severity [11]. MBL, a member of the col-
lectin family, mediates carbohydrate dependent activation of
the classical complement pathway and play an important role
in pattern recognition and innate immune defense [12,13].
MBL deﬁciency has been associated with increased susceptibil-
ity to many infectious diseases, including viral infections [14]. In
a prospective study, the levels of theMBL protein were found to
be higher inDHF patients than inDF individuals [15]. However
a recent study by Avirutnan et al. [16] examined the role of the
complement system in protection against DENV infection,
and the results provide support for an important role of the com-
plement system in controlling DENV infection and potentially
inﬂuencing the severity of dengue disease in humans. Avirutnan
et al. [16] also demonstrated that the MBL pathway was critical
for neutralization of both insect and mammalian cell-derived
DENVserotype 2 (DENV2). Shresta et al. [10] study found a po-
sitive correlation between MBL concentration in human serum
and the level of DENV2 neutralizing activity, indicated a de-
pressed level of MBL protein or its activity as it is an indepen-
dent risk factor for DENV infection’s morbidity and mortality.
Several mutations in the MBL gene have been associated
with a marked reduction in serum MBL levels and MBL-med-
iated complement activation [17]. A study that performed in
Vietnam by Loke et al. [12] found that there were no signiﬁcant
differences in MBL genotypes or allele frequencies between
DHF patients and controls. This study showed that individu-
als with low serum MBL concentrations due to a variant
MBL allele do not impact the risk of DHF/DSS.
Mutation in the promoter region of MBL2 resulting in low
serum levels of MBL has been reported [18]. According to a
study in Brazil, a combination of SNP markers associated with
the low producer phenotype of MBL (low levels of MBL), sig-
niﬁcantly associates with DF but not DHF and it protects
against the development of thrombocytopenia associated with
severe dengue phenotype [19]. However, high MBL levels ap-
pear to be correlated with severe disease [15]. Experiments
by Avirutnan et al. [16] with sera obtained from individuals
with different levels of MBL2 due to known polymorphisms
in the MBL2 gene corroborated the positive correlation be-
tween human MBL2 levels and neutralization of DENV2. This
result linked together to subsequent ﬁndings related to humans
with particular polymorphisms in the MBL2 gene suggested
that the MBL pathway contributes to protection against
DENV infection in humans [10].2.2. Toll-like receptor 4 (TLR4)
TLR4 is a key receptor for the lipopolysaccharide (LPS)
components of Gram-negative bacteria and for structures of
mycobacteria, fungi, and malarial parasites [20]. Two common
non-synonymous polymorphisms in the human TLR4 gene
(referred to as Asp299Gly and Thr399Ile based on the amino
acid permutations they encode) potentially impact function of
the receptor [21] and expression of these mutants in vitro shows
reduced activation in response to LPS [22]. Some studies con-
cerning TLR4 polymorphisms and their association with many
infectious diseases, including sepsis, Gram-negative infections,
tuberculosis, malaria and respiratory syncytial virus have been
reported [23]. Recently, Lavoie et al. [24] found that TLR4polymorphisms inﬂuence bronchopulmonary dysplasia severity
in some populations of high-risk preterm infants.
In Central Java, Indonesia, Djamiatun et al. [25] investi-
gated the inﬂuence of TLR4 polymorphisms Asp299Gly and
Thr399Ile for susceptibility and severity of DENV infection.
They investigated 201 Javanese children with DHF and 179
healthy controls. The TLR4 299/399 genotype was found in
ﬁve patients and four controls. Prevalence of this genotype
did not differ signiﬁcantly between controls and DHF patients
or between patients with different severities of DHF. Djamia-
tum group also found that vascular leakage in patients with
different TLR4 genotypes did not differ. Thus, the 299/399
TLR4 haplotype has only a minor inﬂuence on the susceptibil-
ity and severity of complicated DENV infection.
2.3. Fcc receptor II (FccRII)
FccRII is a widely distributed receptor for all subclasses of
IgG and it is able to mediate antibody dependent enhancement
(ADE) in vitro by binding to virus-IgG complexes [26]. Char-
eonsirisuthigul et al. [27] demonstrated that DENV infection
of human acute monocytic leukemia 1 (THP-1) cells via FcR
suppressed the transcription and production of IL-12, IFN-c,
TNF-a, and nitric oxide but enhanced the expression of anti-
inﬂammatory cytokines IL-6 and IL-10. This indicates that
FcR receptor is important in DENV infection pathogenesis
by mediating ADE [13]. A polymorphism at 131 position of
the FccRIIA gene, an arginine to histidine substitution,
changes the IgG binding afﬁnity of the receptor, with reduced
opsonization of IgG2 antibodies causally associated with the
arginine variant [28]. There is evidence that homozygotes for
the arginine variant are more susceptible than homozygotes
for the histidine variant to infections with encapsulated bacte-
ria [29]. Loke et al. [12] performed a study in Vietnam to inves-
tigate that homozygosity for the arginine variant might be
associated with a reduced risk of DHF caused by ADE. They
found that neither genotype nor allele frequencies for the
FccRII polymorphism were signiﬁcantly different between
DHF patients and controls. However, homozygote for argi-
nine variant showed moderate associations with resistance to
the most severe form of DHF.
2.4. Vitamin D receptor (VDR)
VDR mediates the immunoregulatory effects of 1,25-
dihydroxyvitamin D3 (1,25D3), which activates monocytes,
stimulating cellular immune responses and suppressing
immunoglobulin production and lymphocyte proliferation
[30]. The tt genotype of a SNP at position 352 of the VDR gene
has been associated with tuberculoid leprosy, enhanced clear-
ance of hepatitis B virus (HBV) infection and resistance to pul-
monary tuberculosis [17]. Recent studies suggested a protection
association between this SNP with infectious diseases including
tuberculosis [31], Leishmania major [32], Human Immunodeﬁ-
ciency Virus (HIV) [33] and Staphylococcus aureus infection
[34]. These associations led to the suggestion that the tt genotype
may be associated with a relatively stronger TH1-type cellular
immune response than the TT genotype; interestingly, 1,25D3
has been found to alter IL-12 expression and dendritic cell
(DC) maturation [35].
Study by Loke et al. [12] in Vietnam found that genotype
frequencies for VDR polymorphism did not differ between
4 H. Harapan et al.DHF cases and controls, but allele frequency analysis showed
that there was an association between VDR polymorphism
and DHF disease severity. This result suggests that the t allele
may be protective against severe DHF. Expression of VDR
may affect the susceptibility to DHF since it activates B and
T lymphocytes and affects monocytes, the main sites of DENV
infection.[17]. However, further work will be required both to
conﬁrm this association and to explore possible mechanisms.
2.5. Cytotoxic T-lymphocyte antigen 4 (CTLA-4)
The pathogenesis of DHF has been considered to be massive
immune activation of T cells. Abnormal expression of the im-
mune regulatory molecules, CTLA-4 and TGF-b1, leads to
disturbances of regulatory T cell immune response [36]. The
CTLA-4 together with cluster differentiation (CD)-28, a
co-stimulatory molecule, plays a signiﬁcant role in the T-cell
mediated immune response, which is initiated when the anti-
gen-speciﬁc T-cell surface receptor encounters an antigen pre-
sented by the antigen presenting cell (APC) complexes with
major histocompatibility complex (MHC) class II molecule
[37].
The CTLA-4 gene located on chromosome 2q33 includes a
SNP in exon 1, where there is an adenine (A) for guanine (G)
substitution at position 49 resulting in a threonine for alanine
substitution in the expressed protein [38]. It has been reported
that the CTLA-4 +49 A allele yields a variant that interacts
more with B7.1 (CD28 ligand) and endows Tregs (regulatory
T cell) with greater suppressive activity [37,39]. Similarly, T
cells from patients with this allele displayed a diminished pro-
liferative response which was more susceptible to intervention
by CTLA-4 blockade [40].
Polymorphism of CTLA-4 gene has been associated with an
increased risk of autoimmune and infectious diseases [41]. This
gene polymorphism has been associated with parasitic infec-
tions [41], Human Papilloma Virus (HPV) infection [42], inva-
sive bacterial infections [43], autoimmune hepatitis and
primary biliary cirrhosis [44], and clearance of HBV [45]. Re-
cently, Duan et al. [46] conﬁrmed that CTLA-4 +49 A/G
polymorphism confer susceptibility to chronic HBV infection
in Chinese Han patients. A study in Taiwan by Chen et al.
[36] found that the presence of the CTLA-4 +49 G allele
and TGF-b1 509 CC genotype increased the susceptibility
to risk of DHF and signiﬁcantly higher virus load.
2.6. Dendritic cell-speciﬁc ICAM3-grabbing non-integrin (DC-
SIGN)
Dendritic cells (DCs) are major in vivo targets of DENV, DC
interact with glycan moieties on the DENVE protein and medi-
ate the entry of all four serotypes, and thus it can confer DENV
susceptibility to normally nonpermissive cells [47]. DC-SIGN, a
C-type lectin, is expressed on subsets of DCs [48] and is encoded
byCD209 gene located on chromosome 19p13.3 [49]. DC-SIGN
plays an important role in the early interaction of a pathogen
with a DC and has a key role in DC-T cell interaction, DC
migration, and pathogen uptake [50]. DC-SIGN is known to
be the major DENV receptor on human DCs and induces
endocytosis of several pathogens, including DENV [50,51].
Numerous SNPs in DC-SIGN gene have been reported,
one of these SNPs represents a guanine (G) to adenine (A)
transition at position 336 within the DC-SIGN promoter(DC-SIGN 336 A/G) [50]. This variant affects DC-SIGN
promoter activity with multiple transcription factor binding
sites for transcription factors [52]. This variant has been
associated with an increased risk for parenteral acquisition
of HIV infection [53], increased susceptibility for tuberculosis
[48], human T-cell lymphotropic virus type 1 [54] and Kawasa-
ki disease [55].
The effect of DC-SIGN 336 A/G was assessed in a Thai
study conducted by Sakuntabhai et al. [52]. The G allele
(GG or GA) was found to be infrequent in individuals with
DF compared with controls and no protective effect was seen
in DHF. However, the G allele was strongly associated with
risk of DHF. Recently, a strong association between GG/
AG genotypes of DC-SIGN and risk of DHF was found when
compared with DF, other non-dengue febrile illnesses (OFI)
and controls [50]. The AA genotype was associated with pro-
tection against DENV infection compared with OFI and con-
trols. Moreover, Wang et al. [50] also generated monocyte
derived dendritic cells (MDDCs) from individuals with AA
or AG genotype of DC-SIGN to study the viral replication
and immune responses for functional validation. They found
that MDDCs from individuals with AG genotype with a high-
er cell surface DC-SIGN expression had a signiﬁcantly higher
TNF-a, IL-12p40, and interferon-inducible protein-10 (IP-10)
production than those with AA genotype in response to
DENV infection. However, the viral replication in MDDCs
with AG genotype was signiﬁcantly lower than those with
AA genotype. This study conﬁrmed that DC-SIGN 336 A/
G contributes to susceptibility to DENV infection and compli-
cation of DHF and this SNP with AG genotype affects the cell
surface DC-SIGN expression related to immune augmentation
and less viral replication.
2.7. Transporters associated with antigen processing (TAP)
TAP, a member of the ATP binding cassette (ABC) trans-
porter family, plays a crucial role in the processing and presen-
tation of the MHC class I restricted antigens [56]. MHC class I
molecules present intracellular peptides to cytotoxic T cells
[57]. The antigen peptides are generated in the cytosol and
TAP translocates antigenic peptides from cytoplasm into the
endoplasmic reticulum (ER) for binding the MHC class I mol-
ecules for presentation to CD8+ cytotoxic T cells [57,58]. The
translocation of cytosolic peptides into ER lumen is a crucial
step in the presentation of intracellular antigen to T cells by
MHC class I molecules [57].
TAP consists of two homologous subunits, TAP1 and
TAP2 [57]. The genes for TAP are located within the MHC
class II region of chromosome 6 [58]. The polymorphisms lo-
cated at these gene coding regions affect the speciﬁcity of pep-
tide presentation and transport process which furthermore
alter the immune response regulation [58,59]. Several polymor-
phisms that have been reported in TAP gene, several dimor-
phic sites are TAP1333 (Aﬁ G, Ileﬁ Val), TAP1637 (Aﬁ G,
Aspﬁ Gly), TAP2379 (Gﬁ A, Valﬁ Ile), TAP2565 (Gﬁ A,
Alaﬁ Thr) and TAP2665 (Aﬁ G, Thrﬁ Ala) [60]. Polymor-
phisms in TAP gene have been associated with systemic lupus
erythematosus [61], rheumatoid arthritis [62], allergic rhinitis
[60], hypersensitivity pneumonitis [63] and TB [58].
The ﬁrst study on TAP gene polymorphism and DENV
infection was conducted by Soundravally & Hoti [64] in India.
They found that the frequencies of Val at TAP1333 were in-
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The frequency of genotype TAP1333 Ile/Val was signiﬁcantly
higher in DHF compared with control or DF patients. This
research conﬁrmed that heterozygous pattern at the TAP1333
locus genotypes confers susceptibility to DHF. The risk of
DHF was increased 2.58 times with the TAP1333 Ile/Val geno-
type. In the other publication in 2008, Soundravally & Hoti
found that homozygous patterns for Ile at TAP1333, Asp at
TAP1637 and Val at TAP2379 were found to be a protective fac-
tor against DHF and DSS development among the primary-in-
fected individuals, respectively [65]. From this study, it is
possible to state that homozygous patterns at TAP1333,637
and TAP2379 probably lead to selection of immunodominant
epitopes that bring protective immunity against primary DHF.
2.8. Janus kinase 1 (JAK1)
JAK/signal transducers and activators of transcription (JAK/
STAT) cascade is essential for cytokines, growth factors, G-
proteins and hormones and the STA of JAK/STAT pathway
controls the signal transduction between cell surface receptors
and the nucleus [66,67]. JAK1 is essential for signaling for
certain type I and type II cytokines [68]. It interacts with the
common gamma chain (cc) of type I cytokine receptors, to eli-
cit signals from IL-2, IL-4 and gp130 receptor family [68].
JAK1 is also important for transducing a signal by type I
(IFN-a/b) and type II (IFN-c) interferons, and members of
the IL-10 family via type II cytokine receptors [68].
The JAK family consists of four members, JAK1, JAK2,
JAK3 and TYK2 [67]. JAK-1 gene, which is located on chro-
mosome 1p31.1, has a highly polymorphic ﬂanking region [67].
JAK family gene polymorphism is associated with erythrocy-
tosis [69], leukemias [69,70], polycythemia vera [71], Crohn’s
disease [66], gigantism [69] and cardiovascular diseases [72].
A recent study found JAK-1 polymorphisms are associated
with higher susceptibility to asthma [67].
Silva et al. [73] genotyped about 593 SNPs in 56 genes across
the type 1 interferon (IFN) response pathway as well as other
important candidate genes. By single locus analysis comparing
DHF with DF, 11 of the 51 markers with p< 0.05 were in the
JAK1 gene. This association remained signiﬁcant after control-
ling for ancestry and income. An association between DHF and
JAK1 polymorphisms is in agreement with expression proﬁles
showing generalized decreased type 1 IFN-stimulated gene
expression in these patients. These arguments support with ani-
mal studies. Mouse studies have shown that some components
of the type 1 IFN response pathway can control the response
to all ﬂaviviruses [74]. In addition, ﬂaviviruses have developed
speciﬁc strategies to neutralize signaling downstream of the
receptor to circumvent this response [75]. Supportive evidence
is also provided by a global analysis of expression proﬁles in
individuals with DSS compared with DF, which indicated that
multiple IFN-a-regulated genes were under-expressed [76]. This
study provides evidence that polymorphisms in the JAK1 gene,
including this one, may provide differential susceptibility to
DENV infection.
2.9. Interleukin-4 (IL-4)
Several studies have shown that concentrations of multiple
cytokines, soluble receptors and other mediators are signiﬁ-
cantly increased during severe dengue infections [77]. DSS isassociated with marked changes in vascular permeability
potentially due to inﬂammatory mediators and complement
activation [13]. DENV-infected DC induces the interacting T
cells to proliferate and produce some of cytokines such as
IL-4 [78]. The key cytokines that have been associated with
DHF include the shift from Th1-type response in DF to the
Th2- type cytokine response in DHF, with increased levels of
IL-10 and IL-4 [79]. IL-4 is primarily produced by Th2 subset
of CD4+ T cells [12]. It regulates B cell growth and IgG class
switching, as well as suppresses Th1-type responses [12].
An SNP identiﬁed within the IL-4 promoter has been
reportedly associated with increased levels of gene transcrip-
tion [80]. Interestingly Loke et al. [12] found no differences be-
tween cases and controls for the IL-4 promoter polymorphism,
neither at the genotypic level nor at the allelic level. However,
higher plasma levels of IL-4 have been found in patients with
severe DENV infections [13].
2.10. Interleukin-1 receptor antagonist (IL-1RA)
The IL-1 family consists of IL-1 alpha (IL-1a), IL-1 beta (IL-
1b), and IL-1ra [81]. IL-1a and IL-1b that bind to IL-1 receptor
(IL-1R) and initiate an inﬂammation cascade to induce vascular
dilation and fever [82]. IL-1ra is involved in the regulation of IL-
1-mediated inﬂammatory responses by competitive binding to
IL-1R [17]. The polymorphic region within intron 2 of the IL-
1RN* gene that contains variable numbers of tandem repeats
(VNTR) of 86 bp, ﬁve alleles of the IL-1RN*have been reported
(*1–*5), corresponding to 2, 3, 4, 5 and 6 copies of the 86-bp se-
quence respectively [7]. A two-repeat allele (IL-1RA2) of an 86-
base pair VNTR in the IL-1RA gene is associatedwith increased
serum levels of IL-1ra [7]. Thus, persons homozygous for allele 2
of the IL-1RA gene (IL1RN*2) have a more prolonged and
more severe proinﬂammatory immune response than persons
with other IL-1RA genotypes [82]. Some studies have shown
that there are negative associations between IL1RN*2 homozy-
gosity and vaginal colonization with mycoplasmas, infection
with human cytomegalovirus and Epstein-Barr virus, and HIV
proliferation [82]. Recently, Hsu et al. [81] found that IL-1RA
polymorphism was associated with the risk of multidrug-resis-
tant Acinetobacter baumannii-related pneumonia. However,
based on a study in Dong Nai pediatric Centre Vietnam found
no difference neither in genotype nor in allele frequencies of
the IL-1RA repeat polymorphisms between DHF cases and
controls [12].
2.11. Interleukin 6 (IL-6)
IL-6, a pleiotropic cytokine, is a major mediator of fever and
acute-phase reactions and is produced during innate and adap-
tive immune response by T and B lymphocytes, macrophages,
monocytes, ﬁbroblasts and activated endothelium cell (EC),
besides some tumoral cells [13,83]. A study conﬁrmed that
IL-6 mediates derangement of coagulation and ﬁbrinolysis
[84]. Brieﬂy, IL-6 is likely to be associated with dengue diseases
by taking several roles: (a) IL-6 together with other proinﬂam-
matory cytokines potentiates the coagulation cascade; (b) IL-6
downregulates the production of TNF-a and TNF receptors;
(c) IL-6, together with IL-1, is a potent fever inducer [13].
High concentrations of IL-6 have been implicated in capil-
lary leakage and development of hypovolemic shock in pa-
tients with anaphylaxis and meningococcal sepsis [85]. In an
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sera of DENV infected mice [86]. In human, higher levels of
IL-6 are measured in the plasma in patients with severe DENV
infections [87,88].
A biallelic polymorphism within the human IL-6 gene
promoter region (174G/C) has been shown to affect IL-6 tran-
scription in vitro and IL-6 plasma levels [7]. SNP IL-6
174G> C has been related to various infectious diseases
[89]. Moreira et al. [90] found that patients who expressed IL-
6 174 GG (high production of IL-6) promote protection
against DF clinical symptoms development. This association
is based on two biological activities of IL-6. First, IL-6 has an
action in viral eradication by stimulating a TH1 immune re-
sponse, and second IL-6 promotes the decrease of consequential
symptoms to infection, since it inhibits the acute phase of the
inﬂammatory response through induction of pro-inﬂammatory
cytokine antagonists as IL-1ra and soluble TNF receptor
(sTNFR) p55 [90].
A research in Brazil conducted by Moreira et al. [90]
found that there was a negative association between IL-6
174 GC genotype and DF. However, a signiﬁcant statistical
difference with cytokine production phenotypes or alleles was
not observed. Moreira et al. [90] argued that the SNP IL-6
174 G > C is part of a haplotype of SNPs, genetically
and functionally linked, including the positions 634
G> C, 597 G> A, 572 G> C and 373AnTn. Thus,
a speciﬁc polymorphism of this haplotype may exert inﬂuence
on IL-6 transcription, but each SNP would not act indepen-
dently from others.
2.12. Interleukin-10
IL-10 is a major anti-inﬂammatory cytokine that has been
associated with several diseases being considered an important
immunoregulatory mediator produced by monocytes, DCs,
and T and B lymphocytes [91]. IL-10 has been involved in
the thrombocytopenia and hemorrhagic manifestations ob-
served during DENV infection [92]. In addition, plasma levels
of IL-10 correlated with platelet decay in DENV-infected pa-
tients [93] and may modulate the activation of coagulation
[13]. Moreover, IL-10 downregulates the inﬂammatory re-
sponse and creates a proviral survival milieu. Then it inhibits
the expression of tissue factor (TF) and furthermore inhibits
ﬁbrinolysis [13]. Also IL-10 levels have been found to be high
in the sera of DENV infected mice [84] and in patients with
severe DENV infections [94].
IL-10 gene SNPs (1082 A/G, 819 C/T and 592 A/C) in
a group of individuals with the antecedent of DHF during a
secondary infection were studied in Cuba [95]. However, there
were no statistically signiﬁcant differences in the frequencies of
IL-10 allele and genotypes between DHF and control groups.
However, the haplotype (IL-10 1082/819/592) ACC/ATA
carriage was more frequent in DHF than in controls
(OR = 2.54, 95% CI = 1.12 – 5.73, p= 0.02). Perez et al.
[95] also found that individuals with the TNF-a or IFN-c high
genetic variants and IL-10 or TGF-b1 low genetic variants
were more frequently distributed in DHF group compared
with the controls. In addition, associations between the
TGF-b1 low producer genotypes (codon 25 CC and CG)
and IL-10 low producer haplotype (ACC/ATA) with DHF
were found. In the same study, the association between the
TNF-a high/IL-10 low genotype and DHF was also reported.This study suggests that IL-10 low producer haplotype was
associated with DHF.
2.13. Tumor necrosis factor-alpha (TNF-a)
TNF-a, an important proinﬂammatory cytokine, plays a role
in the regulation of cell differentiation, proliferation and
death, as well as in inﬂammation, innate and adaptive immune
responses, and also implicated in a wide variety of human dis-
eases [96]. Several SNPs found in the regulatory region inﬂu-
ence transcription of TNF-a gene and circulating level of
TNF-a [7] and thus increases the susceptibility to human dis-
eases including viral diseases [96]. Dewi et al. [97] performed
experiments showing that TNF-a is capable of increasing
endothelium cell (EC) permeability in vitro, which suggests
its possible role in pathogenesis of DHF. In a mouse model
of DENV-induced hemorrhage, high levels of TNF-a in some
tissues correlated with EC apoptosis and hemorrhage [98].
TNF-a level has been shown to be high in sera of DENV in-
fected mice [86].
Brieﬂy, TNF-a is associated with development of DHF/
DSS by many pathways: (a) TNF-a is a potent activator
of EC and enhances capillary permeability; (b) TNF-a
upregulates expression of TF on monocytes and EC; (c)
TNF-a downregulates expression of thrombomodulin on
EC; (d) TNF-a has a direct effect on production of IL-6,
thus an indirect effect on coagulation and ﬁbrinolysis; (e)
mediates activation-induced death of T cells, and it has
therefore been implicated in peripheral T-cell deletion [13].
In addition, TNF-a induces EC production of reactive nitro-
gen and oxygen species and induces apoptotic cell death,
thus TNF-a has been involved in the pathogenesis of hem-
orrhage [99].
In a clinical study, a positive correlation between soluble
TNF-a concentrations and thrombocytopenia was found
[100]. Another study found that plasma levels of TNF-a is
signiﬁcantly higher in DHF than in DF [101]. Previously
Loke et al. [12] found no association between TNF-a
238 G/A and 308 G/A polymorphisms in Vietnamese
DHF patients when compared with control subjects from
the same population. On the contrary, in a Venezuelan
study Fernandez-Mestre et al. [102] conﬁrmed that the
TNF-a 308 variant allele was present in 30% of partici-
pants with DHF versus 5% in those with DF (OR= 7.58,
95% CI = 1.23–79.2, P= 0.02). Fernandez-Mestre et al.
[102] reported a high association of TNF-a 308A allele
in DF patients with hemorrhagic manifestations, suggesting
it as a possible risk factor for bleedings among DF patients.
In a study conducted in Thailand, the TNF-a 238 A poly-
morphism combined with lymphotoxin-alpha (LTA)-3 hap-
lotype were correlated signiﬁcantly with DHF compared
with DF [103]. More recently, a study by Perez et al. [95]
in Cuba conﬁrmed that the allele distribution of TNF-a pro-
moter polymorphism revealed the association of allele A
(high production of TNF-a) to DHF signiﬁcantly. A higher
frequency of carriers of genotype 308 GG (low production
of TNF-a) was observed in controls, whereas the DHF
group showed a major distribution of AA and AG geno-
types (high production of TNF-a). However, the association
between genotype AA and DHF was not signiﬁcant. An
association of AG genotype to DHF and GG genotype to
controls was observed.
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The pathogenesis of DHF has been considered to be massive
immune activation of T cells. Abnormal expression of the
immune regulatory molecule such as TGF-b1 leads to
disturbances of regulatory T cell immune response [36]. There
are some pathways in which TGF-b1 is associated with devel-
opment of DHF/DSS. TGF-b1 may act as a proinﬂammatory
or anti-inﬂammatory cytokine, depending on its concentra-
tion. Early in DENV infection, low levels of TGF-b1 may trig-
ger the secretion of IL-1 and TNF-a. However, later in
infection, TGF-b1 inhibits the Th1 response and enhances pro-
duction of Th2 cytokines such as IL-10 [13]. TGF-b1 increases
expression of TF on EC and upregulates expression and
release of plasminogen activator inhibitor 1 (PAI-1) [13]. In
several studies, higher plasma levels of TGF-b1 have been
found in patients with severe DENV infections, in particular
in patients with DSS [104,105].
A study during an outbreakofDEN2 inTaiwan, investigated
the contribution of CTLA-4 and TGF-b1 in DHF by analyzing
them for association with virus load in blood and polymor-
phisms of CTLA-4 +49 A/G and TGF-b1 509 C/T [36]. This
study found that the frequency of the TGF-b1 509 CC geno-
type in patients with DHF was signiﬁcantly higher compared
to DF. Moreover, the presence of the CTLA-4 +49 G allele
and TGF-b1 509 CC genotype increased the susceptibility to
risk ofDHFandhigher virus load signiﬁcantly.A study byPerez
et al. [95] in Cuba was conducted to conﬁrm the association of
TGF-b1 polymorphism (10 T/C and 25 G/C) to DENV
infection. They found no signiﬁcant neither allele nor genotypes
differences in codon 10 in between DHF and control groups.
However, a signiﬁcant difference was found for codon 25 poly-
morphism beingG allele andGG genotype predominant in con-
trols. Perez et al. [95] also found an association between the
TGF-b1 low producer genotypes (25 CC and CG) and IL-10
low producer haplotype (ACC/ATA) with DHF. This result
links a high production of TGF-b1 with protection or a mild
clinical outcome of dengue infection.
2.15. Interferon-gamma (IFN-c)
IFN-c, produced by CD3 T and natural killer (NK) cells, char-
acterizes the Th1 pattern and has a wide range of effects,
monocyte/macrophage activation being the most important
[106]. IFN-c released from T lymphocytes is activated during
DENV infections [17]. T cells interact with DENV-infected
cells and produce IFN-c [107]. IFN-c with other cytokines
which activate macrophages or nearby vascular endothelium,
promote leukocyte and plasma extravasations [88,101]. IFN-
c was found to be signiﬁcantly higher in DHF and DSS pa-
tients than in DF patients [88,100,101]. A higher level of
IFN-c has been also associated with dengue severity [93].
Perez et al. [95] conducted a study to conﬁrm the association
of SNP IFN-c 874A/T to DHF in Cuba. They found that al-
lele T and TT genotype (high production IFN-c) predominated
in the DHF group but without signiﬁcance. Then, they assessed
the combined effect of SNP IFN-c with other cytokine genes’
polymorphism. Interestingly, although high production IFN-
c 874T allele did not associate with DHF, the presence of this
variant, conjointly with the high production TNF-a 308 A
variant in the same individual, was signiﬁcantly associated with
DHF. Besides, IFN-c 874 T allele in combination with thelow production TGF-b1 genotype or IL-10 haplotype, also
show signiﬁcant association with DHF. These results suggest
that the high IFN-c production does not deﬁne per se the den-
gue illness outcome with regard to severity. This study has
shown a similar result with previous study of Sierra et al.
[108] in which the peripheral blood mononuclear cells (PBMC)
from DEN1–immune individuals exposed to a DEN1/2 ex vivo
challenge had shown a higher TNF-a and IFN-c gene expres-
sion compared with DEN1 homologous stimulation.2.16. Human platelet antigens (HPA)
HPA are speciﬁc antigens carried by platelet glycoproteins,
and 22 kinds of alloantigens have been ofﬁcially named includ-
ing 6 known systems, HPA-1  5 and 15 [109]. Platelet-speciﬁc
antigens are membrane glycoproteins, which are largely
responsible for interaction between platelets and the endovas-
cular wall components [64]. Thrombocytopenia is one of the
major pathogenic outcomes in the severe form of dengue dis-
ease. Autoimmune destruction, abnormal activation and
aggregation of platelets were demonstrated as some of the
causes of this condition [64]. DENV–antibody complexes have
been detected on platelets from patients with DHF/DSS, sug-
gesting a role of immune-mediated destruction of platelets in
thrombocytopenia.
Polymorphisms in the genes encoding these proteins
could lead to single-amino-acid substitutions that deﬁne a
number of allelic variants that are immunologically distinct.
Previous study found that the polymorphism in HPA-1 and
HPA-2 did not correlate with an increased risk of stroke
[110], a recent study conﬁrmed that HPA-1/HPA-2 haplo-
types are considered to be a major risk factor for coronary
artery disease in middle-aged Tunisians [111]. A study in
China indicated no signiﬁcant difference in HPA-1 genotype
distributions between hemorrhagic fever with renal syndrome
(HFRS) patients and controls, however a signiﬁcant differ-
ence was found in HPA-3 genotype and allele frequencies
[112]. A recent study conﬁrmed that polymorphism in
HPA-1 genotype is associated with progression of ﬁbrosis
in chronic hepatitis C [113].
A study carried out in India found that the frequencies of
HPA-1b at HPA-1 were increased among DSS in compari-
son to controls [64]. A signiﬁcantly greater proportion of
DHF patients demonstrated HPA-1a/1a and HPA2a/2b
genotypes than DF patients. DSS patients were more likely
to be heterozygous at HPA-1 than DHF. This study sug-
gested that HPA-1a/1a and HPA-2a/2b genotypes confer
susceptibility to DHF and the HPA-1a/1b genotype was
determined to be a genetic risk factor for DSS. This study
indicated that structural variants of HPA-1 and HPA-2 ap-
pear to associate with the susceptibility to DF and DHF,
respectively. HPA-2 plays a role in the interaction of platelet
to ﬁbrinogen and von Willebrand factor [114]. HPA2 is
responsible for the aberrant activation of the clotting mech-
anism and increases vascular permeability. In addition,
cross-reacting anti DEN antibodies against HPA-2a antigen
might be involved in the pathogenesis of DHF [64]. Autoim-
munity against these antigens, mediated by the binding of
DEN antibody–virus complex to the HPA glycoproteins,
might be one of the reasons for platelet destruction in
DEN infection.
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In summary, we have shown that there are many scientiﬁc evi-
dences that have proven the fact indicating host genetic factors
as important components in dengue disease. SNP in human
genes such as MBL2, TNF-a, Fcc receptor, CTLA-4, TGF-
b1, HPA, DC-SIGN, TAP, VDR, and JAK1 has been associ-
ated with protection, susceptibility and severity of DENV
infection. However, SNP in IL-4, IL-1RA, IFN-c, IL-6,
TLR4 and IL-10 gene did not show association with DENV
infection. Further analysis of the genetic basis of severe DENV
disease in different populations may contribute to the develop-
ment of new preventative and therapeutic interventions.4. Disclosure statement
There is no conﬂict of interest in writing of this manuscript.References
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